Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model.

Ide SmetsMatthijs VersteeghSimone HuygensCato E A Corsten Beatrijs H A Wokke Joost J F M Smolders

Published in: Multiple sclerosis journal - experimental, translational and clinical (2023)

Our model showed no clear difference in cost-effectiveness between ocrelizumab and ofatumumab. Hence, prescribing the least costly anti-CD20 mAb can democratise MS care without a loss in health benefits.

Keyphrases

multiple sclerosis
healthcare
public health
mental health
primary care
white matter
health information
mass spectrometry
palliative care
nk cells
ms ms
emergency department
adverse drug
climate change
social media
systemic lupus erythematosus
health insurance